RxDoctor Payments Data

Andrew Ochiltree

Optometrist · Casper, WYNPI 1457544199

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $878 of the $1,007 with a category attached, or 87.2%. It is spread thinly across 13 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $335 and has fallen 50.9% since, to $165 in 2025.

$1,007in general payments, 2019–2025

Across 39 payments — averaging $25.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$233
  • Sight Sciences, Inc.$172
  • Optos, Inc.$145
  • AbbVie$142
  • Sun Pharmaceutical Industries Inc.$102
  • Bausch & Lomb Americas Inc.$46
  • plus $167 from 7 others

What the payments were for

  • Food & beverage$87887%
  • Entertainment$12913%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,007 in reported general payments places this provider in the 85th percentile of 102 optometrist providers in Wyoming.

See all optometrist providers in Wyoming

Medicare billing

Part B allowed, 2024
$133,398
Medicare patients
613
Services billed
1,597

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine40$43,024
LumiganBimatoprost50$26,179
Travoprost39$11,816
Latanoprost452$4,870
Timolol Maleate137$1,674
Prednisolone Acetate32$1,374
Tobramycin-DexamethasoneTobramycin/Dexamethasone21$1,238
Fluorometholone11$874
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat56$498
Brimonidine Tartrate47$378
Dorzolamide Hcl18$228
Ofloxacin17$220
ErythromycinErythromycin Base20$191
Acyclovir21$118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$142$69,20290 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 102 optometrist providers in Wyoming.

Other optometrist in Casper

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →